-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 18, 2021, Dicerna Pharmaceuticals, which focuses on the development of RNAi therapy, announced that it has reached a final agreement with Novo Nordisk
.
Novo Nordisk will spend approximately US$3.
Speed up Novo Nordisk's RNAi drug development and expand the application of RNAi technology
Since 2019, Novo Nordisk and Dicerna have been research partners, using Dicerna's proprietary GalXC RNAi platform technology to discover and develop RNAi therapies
.
The cooperation between Novo Nordisk and Dicerna includes the exploration of more than 30 hepatocyte targets, which may provide more for diseases including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.
RNAi therapy reduces the expression of disease-causing proteins by targeting and silencing mRNA that directs protein synthesis
.
It can be used to target disease-causing genes that cannot be reached by conventional antibodies and small molecule drugs
Dicerna's technology platform can effectively deliver therapies to multiple tissues such as the liver, central nervous system, muscles, etc.
▲Dicerna's RNAi technology platform (picture source: Dicerna official website)
▲Dicerna's RNAi technology platform (picture source: Dicerna official website) Mr.
Marcus Schindler, Executive Vice President and Chief Scientific Officer of Novo Nordisk, said: “The acquisition of Dicerna has accelerated Novo Nordisk’s research in the field of RNAi and expanded the use of RNAi technology
.
Dicerna’s RNAi drug development engine and intracellular delivery Combining technology with our understanding of disease biology and our deep ability to target tissues through peptides and proteins, we may expand our R&D pipeline to patients with chronic diseases such as diabetes, obesity, cardiovascular disease and NASH, as well as endocrine disorders and Patients with rare diseases such as bleeding disorders provide life-changing precision medicines
Original English: https://investors.
dicerna.
com/news-releases/news-release-details/novo-nordisk-acquire-dicerna Original English: https://investors.
